These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32431568)

  • 1. Short-term treatments for acute cardiac care: inotropes and inodilators.
    Guarracino F; Zima E; Pollesello P; Masip J
    Eur Heart J Suppl; 2020 May; 22(Suppl D):D3-D11. PubMed ID: 32431568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry.
    Mebazaa A; Motiejunaite J; Gayat E; Crespo-Leiro MG; Lund LH; Maggioni AP; Chioncel O; Akiyama E; Harjola VP; Seferovic P; Laroche C; Julve MS; Roig E; Ruschitzka F; Filippatos G;
    Eur J Heart Fail; 2018 Feb; 20(2):332-341. PubMed ID: 28990358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
    Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
    ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion.
    Nieminen MS; Buerke M; Cohen-Solál A; Costa S; Édes I; Erlikh A; Franco F; Gibson C; Gorjup V; Guarracino F; Gustafsson F; Harjola VP; Husebye T; Karason K; Katsytadze I; Kaul S; Kivikko M; Marenzi G; Masip J; Matskeplishvili S; Mebazaa A; Møller JE; Nessler J; Nessler B; Ntalianis A; Oliva F; Pichler-Cetin E; Põder P; Recio-Mayoral A; Rex S; Rokyta R; Strasser RH; Zima E; Pollesello P
    Int J Cardiol; 2016 Sep; 218():150-157. PubMed ID: 27232927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey.
    Filippatos G; Farmakis D; Bistola V; Karavidas A; Mebazaa A; Maggioni AP; Parissis JT
    Eur Heart J Acute Cardiovasc Care; 2014 Mar; ():. PubMed ID: 24595245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan.
    Agostoni P; Farmakis DT; García-Pinilla JM; Harjola VP; Karason K; von Lewinski D; Parissis J; Pollesello P; Pölzl G; Recio-Mayoral A; Reinecke A; Yerly P; Zima E
    Card Fail Rev; 2019 Nov; 5(3):155-161. PubMed ID: 31768272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.
    Bouchez S; Fedele F; Giannakoulas G; Gustafsson F; Harjola VP; Karason K; Kivikko M; von Lewinski D; Oliva F; Papp Z; Parissis J; Pollesello P; Pölzl G; Tschöpe C
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):617-624. PubMed ID: 30402660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.
    Chioncel O; Mebazaa A; Harjola VP; Coats AJ; Piepoli MF; Crespo-Leiro MG; Laroche C; Seferovic PM; Anker SD; Ferrari R; Ruschitzka F; Lopez-Fernandez S; Miani D; Filippatos G; Maggioni AP;
    Eur J Heart Fail; 2017 Oct; 19(10):1242-1254. PubMed ID: 28463462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
    Crespo-Leiro MG; Anker SD; Maggioni AP; Coats AJ; Filippatos G; Ruschitzka F; Ferrari R; Piepoli MF; Delgado Jimenez JF; Metra M; Fonseca C; Hradec J; Amir O; Logeart D; Dahlström U; Merkely B; Drozdz J; Goncalvesova E; Hassanein M; Chioncel O; Lainscak M; Seferovic PM; Tousoulis D; Kavoliuniene A; Fruhwald F; Fazlibegovic E; Temizhan A; Gatzov P; Erglis A; Laroche C; Mebazaa A;
    Eur J Heart Fail; 2016 Jun; 18(6):613-25. PubMed ID: 27324686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: current data, clinical use and future development.
    Nieminen MS; Fruhwald S; Heunks LM; Suominen PK; Gordon AC; Kivikko M; Pollesello P
    Heart Lung Vessel; 2013; 5(4):227-45. PubMed ID: 24364017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry.
    Spinar J; Parenica J; Vitovec J; Widimsky P; Linhart A; Fedorco M; Malek F; Cihalik C; Spinarová L; Miklik R; Felsoci M; Bambuch M; Dusek L; Jarkovsky J
    Crit Care; 2011; 15(6):R291. PubMed ID: 22152228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of inotropes and inodilators on renal function in acute cardiac care.
    Zima E; Farmakis D; Pollesello P; Parissis JT
    Eur Heart J Suppl; 2020 May; 22(Suppl D):D12-D19. PubMed ID: 32431569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?
    Rafouli-Stergiou P; Parissis JT; Anastasiou-Nana M
    Expert Opin Pharmacother; 2012 Dec; 13(18):2637-47. PubMed ID: 23170968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical inotropes and new cardiac enhancers.
    Parissis JT; Farmakis D; Nieminen M
    Heart Fail Rev; 2007 Jun; 12(2):149-56. PubMed ID: 17487580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of levosimendan in acute heart failure.
    Harjola VP; Giannakoulas G; von Lewinski D; Matskeplishvili S; Mebazaa A; Papp Z; Schwinger RHG; Pollesello P; Parissis JT
    Eur Heart J Suppl; 2018 Dec; 20(Suppl I):I2-I10. PubMed ID: 30555279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Uhlig K; Efremov L; Tongers J; Frantz S; Mikolajczyk R; Sedding D; Schumann J
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009669. PubMed ID: 33152122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.